We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-11.09%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$171M
AUM Growth
-$23.6M
Cap. Flow
+$3.84M
Cap. Flow %
2.25%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$7.04M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$2.59M
2
ALMS
Alumis Inc
ALMS
+$387K
3
SLRN
ACELYRIN
SLRN
+$223K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.47B
$82.2M 48.17%
4,289,304
– –
ALMS
2
Alumis Inc
ALMS
$1.44B
$21.9M 12.83%
2,787,398
-38,650
-1% -$387K
HRMY icon
3
Harmony Biosciences
HRMY
$2.46B
$18.6M 10.87%
539,194
-75,400
-12% -$2.59M
ALXO icon
4
ALX Oncology
ALXO
$278M
$16.2M 9.49%
9,699,925
– –
ARTV
5
Artiva Biotherapeutics
ARTV
$547M
$15.3M 8.98%
1,519,971
– –
SLRN
6
DELISTED
ACELYRIN
SLRN
$12M 7%
3,806,410
-46,060
-1% -$223K
LYEL icon
7
Lyell Immunopharma
LYEL
$352M
$4.55M 2.66%
+355,110
New +$7.04M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q4 2024 Portfolio in Review

As of Q4 2024, venBio Partners held 7 positions worth $171M, down 12% from $194M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q4 2024 filing shows 1 new and 3 reduced positions. Its largest new stake was Lyell Immunopharma: 355,110 shares worth $4.55M. The largest sale was Harmony Biosciences, an estimated $2.59M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's largest Q4 2024 buy was Lyell Immunopharma: 355,110 shares worth $4.55M.
  • venBio Partners's biggest Q4 2024 reduction was Harmony Biosciences, cutting an estimated $2.59M.
  • venBio Partners's ten largest holdings make up 100% of its $171M portfolio in Q4 2024.
  • venBio Partners opened 1 new position and closed 0 in Q4 2024.
  • venBio Partners's portfolio value fell 12% quarter-over-quarter to $171M.

Based on venBio Partners's 13F filing for Q4 2024, filed 14 Feb 2025.